We specialize in giving medicines a new lease of life, ensuring that products will continue to be marketed and distributed responsibly once they have joined the Clinigen portfolio.
By choosing to divest non-core assets to Clinigen SP, you can do more than just realize value, rationalize your portfolio or free up resources: we will maintain niche patient population access to your medicines and invest in the continued goodwill of key opinion leaders.
Our approach is different for each divestment, but in every case we offer the opportunity to deal with a single, responsible buyer who will take on marketing authorizations and manufacturing commitments.
Our ability to operate anywhere in the world, in both licensed and unlicensed markets is unique. With unrivalled logistical, regulatory and market intelligence expertise in dozens of countries, we can take on a medicine in its entirety – giving you the opportunity to divest to a single, responsible new owner with control of our own supply chain and the demonstrated ability to distribute globally.
Efficient and swift transactions
Divesting to one responsible owner with a small, focused team means a fast and smooth transition. It means that your resources are used more efficiently, and transaction costs can be lower.
Maintaining access – and reputation
Maintaining patients’ access to the medicines they have come to rely on is essential, and something we take very seriously. As the only pharmaceutical company that owns its own intellectual property while also serving other businesses through Clinical Trials Supply and Global Access Programs, we have a unique ability to continue to give patients access to their medicines, while maintaining the reputation of the brand.